Mesoblast Limited ( (AU:MSB) ) has provided an update.
Mesoblast Limited announced the commercial availability of Ryoncil® (remestemcel-L) for treating children with acute GVHD in the U.S., following FDA approval. The company is expanding its reach with plans to onboard more transplant centers and increase insurance coverage. Additionally, Mesoblast is progressing with its Revascor® and rexlemestrocel-L therapies, with ongoing FDA discussions and trials aimed at addressing chronic heart failure and low back pain, respectively. The company also strengthened its financial position with a successful global private placement and enhanced its board of directors.
More about Mesoblast Limited
Mesoblast Limited is a global leader in developing allogeneic cellular medicines for treating severe and life-threatening inflammatory conditions. The company’s proprietary mesenchymal lineage cell therapy technology platform targets severe inflammation by releasing anti-inflammatory factors, significantly reducing the damaging inflammatory process.
YTD Price Performance: -31.82%
Average Trading Volume: 400,962
Technical Sentiment Signal: Sell
Current Market Cap: $1.47B
See more insights into MSB stock on TipRanks’ Stock Analysis page.